CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

RYTHM Q3 revenue rises on hemp-derived product growth

By Reuters News


Overview

  • U.S. THC beverage and edibles maker's Q3 revenue rose 4% sequentially to $23.9 mln

  • Company posted Q3 net loss of $0.5 mln, adjusted EBITDA fell from prior quarter

  • No Q4 outlook due to pending regulatory changes affecting hemp-derived THC products


Outlook

  • Company is not providing an outlook for the fourth quarter of 2026 at this time

  • Forthcoming federal and state law changes may restrict sales of hemp-derived THC products after December 11, 2026


Result Drivers

  • HEMP-DERIVED PRODUCT GROWTH - Co said 15% sequential growth in hemp-derived product sales to $6.4 mln drove Q3 revenue increase

  • THC BEVERAGE MOMENTUM - Co reported THC beverage depletions rose about 15% sequentially, reaching an annualized run rate of 320,000 cases

  • RETAIL FOOTPRINT EXPANSION - Co expanded THC beverage retail availability to about 8,000 doors across 18 states in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$23.86 mln

Q3 Net Loss

$533,000

Q3 Operating Expenses

$17.37 mln


Reuters Recommended Reads

  • Nov 3 - Curaleaf Q3 revenue rises 11% on international segment growth

  • Nov 3 - Vext Science Q3 revenue rises 18% year-over-year


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.